Tickers

1. Composite Trajectory Verdict

Given ECL's business model as a diversified global provider of water, hygiene, and infection prevention solutions with recurring service revenue, all three financial statements carry roughly equal weight: the income statement shows pricing power and margin trajectory, the cash flow statement reveals conversion of earnings to cash and acquisition funding capacity, and the balance sheet reflects leverage management after a large acquisition.

Composite Trajectory: Mixed

Revenue, gross margin, and operating cash flow all improved year-over-year in 2025, but GAAP operating income and net income declined slightly due to $162.6 million in special charges (primarily One Ecolab restructuring), while net debt/EBITDA rose from 1.7x to 2.0x and cash fell 48% to fund the $1.6 billion Ovivo Electronics acquisition. The adjusted (non-GAAP) metrics show double-digit growth, but the GAAP figures reflect the near-term cost of restructuring and acquisition integration.

2. Red Flags

• GAAP operating income decreased 2% to $2,737.6 million in 2025 from $2,802.4 million in 2024 despite 2% revenue growth, driven by $162.6 million in special charges vs. a $183.6 million gain in 2024 (10-K 2025-12-31, Consolidated Statements of Operations)
• GAAP net income attributable to Ecolab fell 2% to $2,075.6 million in 2025 from $2,112.4 million in 2024 (10-K 2025-12-31, Consolidated Statements of Operations)
• Net debt/EBITDA increased to 2.0x in 2025 from 1.7x in 2024, with net debt rising 20% to $7,590.1 million (10-K 2025-12-31, Financial Position)
• Cash and cash equivalents declined 48% to $646.2 million at year-end 2025 from $1,256.8 million at year-end 2024 (10-K 2025-12-31, Consolidated Balance Sheets)
• Special (gains) and charges have been significant in three consecutive years: $162.6 million charge in 2025, $183.6 million gain in 2024, $133.9 million charge in 2023 (10-K 2025-12-31, Special (Gains) and Charges)
• The gap between GAAP and adjusted diluted EPS widened: GAAP EPS fell 1% to $7.28 while adjusted EPS rose 13% to $7.53 in 2025 (10-K 2025-12-31, Diluted EPS table)
• $1.6 billion in cash used for acquisitions in 2025 (primarily Ovivo Electronics) vs. $313 million in 2024, funded partly by $1.0 billion in new debt issuance (10-K 2025-12-31, Cash Flows - Investing and Financing Activities)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Reported revenue grew 2% to $16,081.2 million in 2025 from $15,741.4 million in 2024, continuing a three-year upward trend (10-K 2025-12-31, Consolidated Statements of Operations). Gross margin expanded 100 basis points to 44.5% in 2025 from 43.5% in 2024, marking the third consecutive year of improvement (10-K 2025-12-31, Cost of Sales and Gross Profit Margin). However, GAAP operating income declined 2% to $2,737.6 million and GAAP net income fell 2% to $2,075.6 million in 2025, primarily due to $162.6 million in special charges versus a $183.6 million gain in 2024 (10-K 2025-12-31, Operating Income and Net Income tables). SG&A as a percentage of sales improved to 26.5% from 26.9% (10-K 2025-12-31, SG&A Expenses). On a non-GAAP adjusted basis, operating income rose 11% and diluted EPS rose 13% in 2025 (10-K 2025-12-31, Non-GAAP adjusted operating income and Diluted EPS tables).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Cash provided by operating activities increased to $2,952.6 million in 2025 from $2,813.9 million in 2024 and $2,411.8 million in 2023, a three-year compound growth trend (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capital expenditures) grew correspondingly, with capital expenditures of $1.0 billion in 2025 versus $995 million in 2024 and $775 million in 2023 (10-K 2025-12-31, Investing Activities). The company returned $754 million in dividends (up from $664 million in 2024) and repurchased $784 million of shares in 2025 (10-K 2025-12-31, Financing Activities). Cash used for investing activities jumped to $2,707.2 million in 2025 from $433.8 million in 2024, driven by the $1.6 billion Ovivo Electronics acquisition (10-K 2025-12-31, Investing Activities). The cash balance declined to $646.2 million at year-end 2025 from $1,256.8 million at year-end 2024 (10-K 2025-12-31, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew 10% to $24.7 billion at December 31, 2025 from $22.4 billion at December 31, 2024, largely reflecting the Ovivo Electronics acquisition (10-K 2025-12-31, Consolidated Balance Sheets). Goodwill increased to $9.2 billion from $7.9 billion, and other intangible assets rose to $3.7 billion from $3.3 billion (10-K 2025-12-31, Consolidated Balance Sheets). Total debt rose to $8.2 billion from $7.6 billion, with $1.0 billion in new fixed-rate notes issued in 2025 partially offset by €575 million ($674 million) in repayments (10-K 2025-12-31, Financing Activities and Liquidity and Capital Resources). Net debt increased 20% to $7.59 billion from $6.31 billion, pushing net debt/EBITDA to 2.0x from 1.7x (10-K 2025-12-31, Financial Position). Shareholders' equity grew 12% to $9.77 billion from $8.76 billion, supported by retained earnings (10-K 2025-12-31, Consolidated Balance Sheets). The revolving credit facility was extended to March 2030 with $2.0 billion capacity and no borrowings outstanding (10-K 2025-12-31, Liquidity and Capital Resources).

6. Data Gaps

• Quarterly GAAP income statement, cash flow, and balance sheet data for 2026 quarters (Q1, Q2) and 2025 quarters (Q2, Q3) — only annual XBRL data was provided in the filings
• Quarterly segment-level revenue and operating income for 2025 and 2026
• Quarterly free cash flow and capital expenditure detail
• Quarterly debt maturity schedule and covenant compliance metrics
• 2026 full-year guidance or outlook figures (beyond the February 2026 One Ecolab expansion disclosure)